TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
27 hedge funds and large institutions have $44M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
35% more funds holding
Funds holding: 20 → 27 (+7)
5% less capital invested
Capital invested by funds: $46.3M → $44M (-$2.29M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$4.72M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$1.99M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.35M |
| 4 |
WG
Welch Group
Birmingham,
Alabama
|
+$395K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$372K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAF
Tredje AP-fonden
Se-111 91 Stockholm,
Sweden
|
-$2.88M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$2.16M |
| 3 |
PA
Perceptive Advisors
New York
|
-$1.29M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$340K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$67.8K |
TCON Hedge Fund Activity: Q3 2015 in Review
27 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q3 2015, worth a combined $44M — down 5% from $46.3M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new TCON positions and 5 closed out — a net gain of 7 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $4.72M. The largest seller was Tredje AP-fonden, exiting entirely with an estimated $2.88M sold.
- 27 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q3 2015, up from 20 in Q2 2015.
- Funds reported $44M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q3 2015, down 5% quarter-over-quarter.
- 12 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q3 2015 and 5 closed out, a net change of +7 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q3 2015 was Eventide Asset Management, an estimated $4.72M added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q3 2015 was Tredje AP-fonden, an estimated $2.88M sold.
Based on aggregated 13F filings for Q3 2015.